OTCM
ABCZF
Market cap3.12bUSD
Nov 22, Last price
22.25
Name
Abcam PLC
Chart & Performance
P/E
—
P/S
—
EPS
0.59
Div Yield, %
—
Shrs. gr., 5y
2.13%
Rev. gr., 5y
9.18%
Revenues
241m
-36.12%
Net income
136m
P
CFO
104m
+264.00%
Dividend
Mar 19, 20200.04139478 /sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Abcam plc is a prominent life sciences firm specializing in the creation, refinement, and provision of specialized agents and instruments crucial for scientific investigation, diagnostic procedures, and pharmaceutical development. Its diverse product portfolio primarily encompasses primary and secondary antibodies, along with conjugated antibodies and their respective conjugation kits. The company also offers singleplex and multiplex immunoassays, a variety of proteins and peptides (such as cytokines), and genetically modified cell lines and lysates. Additionally, their extensive catalog features other essential items like cellular activity kits, miRNA kits, various biochemical compounds, and tools designed for analyzing cell signaling pathways. Abcam caters to a wide clientele, including scientists and researchers at academic institutions and governmental research establishments, as well as professionals within the pharmaceutical, biotechnology, and diagnostics sectors. With a global footprint, the company maintains a presence across the Americas, Europe, the Middle East, Africa, China, Japan, and the broader Asia Pacific region. All its offerings are available for purchase directly via its online platform. Established in 1998, Abcam plc maintains its corporate headquarters in Cambridge, United Kingdom.
Valuation
Title in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT |